Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evofem Biosciences Inc (NQ: EVFM )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 10, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evofem Biosciences Inc

< Previous 1 2 3 4 5 6 7 Next >
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q1 2024
Evofem Biosciences just reported results for the first quarter of 2024. 
Via InvestorPlace
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Merger Target Expects ‘Fourth Consecutive Year of Net Sales Growth’
Via Investor Brand Network
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q4 2023
Evofem Biosciences just reported results for the fourth quarter of 2023. 
Via InvestorPlace
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Acquisition Target Reports Increased Product Sales, Ongoing Revenue Growth
Via Investor Brand Network
Why Is Evofem (EVFM) Stock Up 85% Today?
Here's one under-the-radar penny stock that investors are buying up big today. But the question is, why is EVFM stock surging? 
Via InvestorPlace
Evofem Biosciences's Return On Capital Employed Insights
Via Benzinga
Evofem Biosciences Return On Capital Employed Overview
  
Via Benzinga
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Potential Acquisition Releases FY 2023 Preliminary Financial Report
Via Investor Brand Network
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
From Brodsky & Smith LLC
Via GlobeNewswire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Definitive Agreement to Acquire Evofem Biosciences Inc.
Via Investor Brand Network
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Is Life Sciences-Focused Aditxt Stock Trading Higher Today?
Aditxt Inc (NASDAQ: ADTX) has agreed to acquire Evofem Biosciences Inc (OTC: EVFM) in consideration of the issuance of a combination of common stock and preferred stock and the assumption of certain... 
Via Benzinga
EVFM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Evofem Biosciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
From Aditxt, Inc.
Via Business Wire
CapitalGainsReport: Thursday’s OTC Watchlist (EVFM, EPAZ, NWBO, VDRM)
CapitalGainsReport: Thursday’s OTC Watchlist (EVFM, EPAZ, NWBO, VDRM) 
Via News Direct
Evofem Biosciences Inc. (OTC:EVFM): Here Are Latest News & Updates
Evofem Biosciences Inc. (OTC:EVFM): Here Are Latest News & Updates 
Via News Direct
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. 
Via Benzinga
Why Evofem Biosciences Shares Are Plunging Today?
Evofem Biosciences Inc's (OTC: EVFM) recently completed the Phase 3 EVOGUARD trial evaluating Phexxi vaginal gel (EVO100) to prevent chlamydia and gonorrhea infection in women but did not achieve its... 
Via Benzinga
4 Analysts Have This to Say About Evofem Biosciences
  Over the past 3 months, 4 analysts have published their opinion on Evofem Biosciences (OTC:EVFM) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS. 
Via Benzinga
Evofem Biosciences Phase 3 EVOGUARD Trial Puts October Catalyst In Play, Here’s Why Investors Are Paying Attention ($EVFM)
Via AB Newswire
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD.... 
Via Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. 
Via Benzinga
Traders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier
Via ACCESSWIRE
Evofem Biosciences Stock Jumps 185% Since June…Here’s Why Its FDA-Approved Phexxi May Add Appreciably To Those Gains In 2/H 2022 ($EVFM)
Via AB Newswire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers 
Via Benzinga
Why Cooper-Standard Is Trading Higher By 70%, Here Are 81 Stocks Moving In Friday's Mid-Day Session
Gainers Assure Holdings Corp. (NASDAQ: IONM) shares jumped 88.8% to $3.9650 after jumping around 104% on Thursday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.